TY - JOUR T1 - Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2020-218152 SP - annrheumdis-2020-218152 AU - Vega Jovani AU - Irene Calabuig AU - Maria Luisa Peral-Garrido AU - Ernesto Tovar-Sugrañes AU - María-del-Carmen López-González AU - Pilar Bernabeu AU - Agustín Martínez AU - Joaquim Esteve-Vives AU - Jose-Manuel León-Ramírez AU - Oscar Moreno-Perez AU - Vicente Boix AU - Joan Gil AU - Esperanza Merino AU - Paloma Vela AU - Mariano Andrés Y1 - 2020/06/25 UR - http://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218152.abstract N2 - The recent outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, has brought about a great concern for the management of patients with inflammatory rheumatic diseases. Rheumatologists and patients are worried about the risk of contagion and suffering a more severe disease, derived from immunosuppressive treatment. Also, for the risk of relapse in case of discontinuing medications. To date, most of these questions remain to be answered.Accordingly, we read with interest the recent paper from D’Silva and coauthors.1 They analysed the outcomes of 52 patients with rheumatic diseases (18 under biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) hospitalised for COVID-19, identifying an independent increased risk of intubation and similar to mortality. These results are welcome and of relevance, but some issues need to be commented. Controls were matched for age, gender and disease duration, but multivariate models repeated adjustment for age. For outcome assessment in COVID-19, some laboratory markers—lymphopenia, troponins2— should have been considered as covariates for the … ER -